{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=20",
    "query": {
      "intervention": "Placebo Saline Infusion",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 906,
    "total_pages": 91,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Saline+Infusion&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T19:38:25.574Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03036488",
      "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1174,
      "start_date": "2017-03-07",
      "completion_date": "2025-10-14",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 47,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03036488"
    },
    {
      "nct_id": "NCT00494832",
      "title": "Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spine Surgery"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-02",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2012-09-14",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 2,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00494832"
    },
    {
      "nct_id": "NCT00899600",
      "title": "Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 102,
      "start_date": "2007-02",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2018-10-18",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00899600"
    },
    {
      "nct_id": "NCT00547664",
      "title": "Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain Management"
      ],
      "interventions": [
        {
          "name": "Hylenex recombinant , morphine, saline",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "HPC Healthcare, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2008-01",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2014-02-28",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 3,
      "location_summary": "Lakeland, Florida • Tampa, Florida • Temple Terrace, Florida",
      "locations": [
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Temple Terrace",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00547664"
    },
    {
      "nct_id": "NCT01657760",
      "title": "Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Dependence"
      ],
      "interventions": [
        {
          "name": "citalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 31,
      "start_date": "2014-05-01",
      "completion_date": "2017-09-01",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 1,
      "location_summary": "West Los Angeles, California",
      "locations": [
        {
          "city": "West Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01657760"
    },
    {
      "nct_id": "NCT03924869",
      "title": "Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiotherapy (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 448,
      "start_date": "2019-06-25",
      "completion_date": "2025-01-20",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03924869"
    },
    {
      "nct_id": "NCT04904562",
      "title": "Angiotensin II for Distributive Shock",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Distributive Shock"
      ],
      "interventions": [
        {
          "name": "Angiotensin II",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2022-06-01",
      "completion_date": "2024-07-01",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04904562"
    },
    {
      "nct_id": "NCT04362189",
      "title": "Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "HB-adMSC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Hope Biosciences Research Foundation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 48,
      "start_date": "2020-06-30",
      "completion_date": "2021-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04362189"
    },
    {
      "nct_id": "NCT05037123",
      "title": "Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Postsurgical Pain"
      ],
      "interventions": [
        {
          "name": "Continuous ketamine infusion",
          "type": "DRUG"
        },
        {
          "name": "Ketamine + Saline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 765,
      "start_date": "2022-01-04",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05037123"
    },
    {
      "nct_id": "NCT03331562",
      "title": "A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreas Adenocarcinoma",
        "Advanced Pancreatic Cancer",
        "Metastatic Pancreatic Cancer",
        "Metastatic Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "paricalcitol",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Translational Genomics Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-12-27",
      "completion_date": "2020-07-10",
      "has_results": true,
      "last_update_posted_date": "2022-12-27",
      "last_synced_at": "2026-10-14T19:38:25.574Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Westwood, Kansas + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03331562"
    }
  ]
}